

Page : 1 of 6

Revised edition no: 2

Date: 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

1. Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name : RONIDAZOLE

Product code : 3034

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use : Active ingredient for veterinary drugs and medicated feeds, premixes and

premixtures.

1.3. Details of the supplier of the safety data sheet

Company identification METAPHARMACEUTICAL IND S.L.

c/ Josep Plà 163, 2° 5° 08020 Barcelona Tel.: 933 089 976

e-mail: info@metapharmaceutical.com

1.4. Emergency telephone number

Phone nr : (+34) 933 089 976

2. Hazards identification

2.1. Classification of the substance or mixture

Hazard Class and Category Code(s), Regulation (EC) No 1272/2008 (CLP)

Not classified.

Classification EC 67/548 or EC 1999/45

* Not classified.

2.2. Label elements

Labelling Regulation EC 1272/2008 (CLP)

Not classified.

Prevention: P280: Wear protective gloves, protective clothing, eye protection, face protection.

P262: Do not get in eyes, on skin, or on clothing.

2.3. Other hazards

Other hazards : None under normal conditions.

METAPHARMACEUTICAL IND, S.L.

c/ Josep Plà 163, 2º 5ª 08020 Barcelona (SPAIN) Tel.: 933 089 976

e-mail: info@metapharmaceutical.com

In case of emergency: (+34) 933 089 976



Page : 2 of 6

Revised edition no : 2

Date : 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

3. Composition/information on ingredients

Substance / Preparation : (1-methyl-5-nitroimidazol-2-yl)methyl carbamate

CAS No :7681-76-7 EC No :231-675-1 Annex No :---REACH Ref. :---Substance.

Contains no other components or impurities which will influence the classification of the product.

4. First aid measures

4.1. Description of first aid measures

Inhalation : Assure fresh air breathing. Allow the victim to rest.

Skin contact : Remove affected clothing and wash all exposed skin area with mild soap and

water, followed by warm water rinse.

Eye contact : Rinse immediately with plenty of water. Obtain medical attention if pain, blinking or

redness persist.

Ingestion : Obtain emergency medical attention. Do NOT induce vomiting. Rinse mouth.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms relating to use : Not expected to present a significant hazard under anticipated conditions of normal

use.

4.3. Indication of any immediate medical attention and special treatment needed

General information : Never give anything by mouth to an unconscious person. If you feel unwell, seek

medical advice (show the label where possible).

5. Fire-fighting measures

5.1. Extinguishing media

Suitable extinguishing media : Foam. Dry powder. Carbon dioxide. Water spray. Sand.

Unsuitable extinguishing media : Do not use a heavy water stream.

Surrounding fires : Use water spray or fog for cooling exposed containers.

5.2. Special hazards arising from the substance or mixture

Hazardous combustion products : Under fire conditions, hazardous fumes will be present.

5.3. Advice for fire-fighters

Protection against fire : Do not enter fire area without proper protective equipment, including respiratory

protection.

Special procedures : Exercise caution when fighting any chemical fire. Avoid (reject) fire-fighting water

to enter environment.

METAPHARMACEUTICAL IND, S.L.

c/ Josep Plà 163, 2° 5ª 08020 Barcelona (SPAIN) Tel.: 933 089 976



Page : 3 of 6

Revised edition no : 2

Date : 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For emergency responders : Equip cleanup crew with proper protection.

Ventilate area.

For non-emergency personnel : Evacuate unnecessary personnel.

6.2. Environmental precautions

Environmental precautions : Prevent entry to sewers and public waters. Notify authorities if product enters

sewers or public waters.

6.3. Methods and material for containment and cleaning up

Clean up methods : On land, sweep or shovel into suitable containers. Minimize generation of dust.

Store away from other materials.

6.4. Reference to other sections

See section 8. Exposure controls/personal protection

7. Handling and storage

7.1. Precautions for safe handling

Handling : Wash hands and other exposed areas with mild soap and water before eat, drink

or smoke and when leaving work.

Technical protective measures : Provide good ventilation in process area to prevent formation of vapour.

7.2. Conditions for safe storage, including any incompatibilities

Storage : Keep only in the original container in a cool, well ventilated place. Keep container

closed when not in use.

Storage - away from : Strong bases. Strong acids. Sources of ignition. Direct sunlight.

7.3. Specific end use(s)

Specific end use(s) : None.

8. Exposure controls/personal protection

8.1. Exposure controls

Personal protection : Avoid all unnecessary exposure.

¡ Respiratory protection¡ Hand protection: Wear approved mask.; Wear protective gloves.

¡ Eye protection¡ Chemical goggles or safety glasses.¡ Others; When using, do not eat, drink or smoke.

8.2. Control parameters

METAPHARMACEUTICAL IND, S.L.

c/ Josep Plà 163, 2° 5° 08020 Barcelona (SPAIN) Tel.: 933 089 976



Page : 4 of 6

Revised edition no: 2

Date: 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

8. Exposure controls/personal protection (continued)

Occupational Exposure Limits : No data available.

9. Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state : Powder.

Colour : White. Yellow-brown. pH value : Not applicable.

Melting point [°C] : 167

Critical temperature [°C] : Not applicable.
Flash point [°C] : Not applicable.
Initial boiling point [°C] : Not applicable.
Final boiling point [°C] : Not applicable.

Solubility : Slightly soluble in water, in chloroform and in ethanol (96%). Very slightly soluble

in ether.

9.2. Other information

10. Stability and reactivity

10.1. Reactivity

Reactivity : Not established.

10.2. Chemical stability

Chemical stability : Stable under recommended storage conditions.

10.3. Possibility of hazardous reactions

Hazardous reactions : Not established.

10.4. Conditions to avoid

Conditions to avoid : Direct sunlight. Extremely high or low temperatures.

10.5. Incompatible materials

Materials to avoid : Strong acids. Strong bases.

10.6. Hazardous decomposition products

Hazardous decomposition products : Fumes. Carbon monoxide. Carbon dioxide.



Page : 5 of 6

Revised edition no : 2

Date : 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

11. Toxicological information

11.1. Information on toxicological effects

Acute toxicity

i Inhalationi Based on available data, the classification criteria are not met.i Dermali Based on available data, the classification criteria are not met.

Rat intraperitoneal LD50 [mg/kg] : 1500

Ingestion : Based on available data, the classification criteria are not met.

- Rat oral LD50 [mg/kg] : 3400

12. Ecological information

12.1. Toxicity

Toxicity information : Not established.

12.2. Persistence - degradability

Persistence - degradability : Not established.

12.3. Bioaccumulative potential

Bioaccumulative potential : Not established.

12.4. Mobility in soil

Mobility in soil : Not established.

12.5. Results of PBT and vPvB assessment

Results of PBT and vPvB assessment: The substance does not fulfil the criteria to be identified as PBT substance or vPvB

substance according to Annex XIII of Regulation REACH.

12.6. Other adverse effects

Environmental precautions : Avoid release to the environment.

13. Disposal considerations

13.1. Waste treatment methods

General : Avoid release to the environment. Dispose in a safe manner in accordance with

local/national regulations.

14. Transport information

14.1. Land transport (ADR-RID)

METAPHARMACEUTICAL IND, S.L.



Page: 6 of 6

Revised edition no: 2 Date: 8 / 11 / 2013

Supersedes: 1 / 4 / 2011

RONIDAZOLE

3034

14. Transport information (continued)

: Unregulated. **General information**

14.2. Sea transport (IMDG) [English only]

General information : Unregulated.

14.3. Air transport (ICAO-IATA) [English only]

General information : Unregulated.

15. Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Safety, health and environmental regulations/legislation specific for

the substance or mixture

: Ensure all national/local regulations are observed.

15.2. Chemical Safety Assessment

Chemical Safety Assessment : It has not been carried out.

16. Other information

Revision : Revision - See : *

: PBT: persistent, bioaccumulative and toxic. Abbreviations and acronyms

vPvB: very persistent and very bioaccumulative

Sources of key data used REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF

THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and

1999/45/EC, and amending Regulation (EC) No 1907/2006

Labelling EC 67/548 or EC 1999/45

Not classified.

: S22 : Do not breathe dust. ; S Phrase(s)

S36: Wear suitable protective clothing.

Further information : None.

In accordance with REACH Regulation (CE) No 1907/2006 and with CLP Regulation (CE) No 1272/2008

DISCLAIMER OF LIABILITY The information in this SDS was obtained from sources which we believe are reliable. However, the information is provided without any warranty, express or implied, regarding its correctness. The conditions or methods of handling, storage, use or disposal of the product are beyond our control and may be beyond our knowledge. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product. This MSDS was prepared and is to be used only for this product. If the product is used as a component in another product, this MSDS information may not be applicable.

End of document

METAPHARMACEUTICAL IND, S.L.

c/ Josep Plà 163, 2° 5ª 08020 Barcelona (SPAIN) Tel.: 933 089 976

e-mail: info@metapharmaceutical.com

In case of emergency: (+34) 933 089 976